Lumida
/DERM
⌘K
Journey Medical Corp

Journey Medical Corp

DERM
$7.23USD↑+1.97%+0.14 today

MARKET CAP

204.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$4
$10

AI Summary

Stalk
Sell NowMedium

DERM remains in early Stage 1 consolidation following a terminal decline and range-bound repair. A late-June breakout failed, evidenced by a Bullish Exhaustion candle, and price is overbought and facing resistance. This leads to a bearish medium-term bias, recommending selling into strength near the breakout region.

  • ↑Q2 2026 revenue of $18.5M up 23% YoY; Adjusted EBITDA positive $2.9M
  • ↑MROSI uptake reached ~36,000 prescriptions, contributing $8.1M revenue
  • ↓Q2 net loss of $0.3M and negative earnings yield signal profit challenges
Full analysis →

Buying

4

institutions

Selling

4

institutions

New Positions

4

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
RT

Renaissance Technologies LLC

Q2 2026

SELL229.70 K1.63 M+-12.80 K+43.0%0.00%
MM

Millennium Management LLC

Q2 2026

SELL110.02 K778.91 K+-273.05 K-56.6%0.00%
BI

Blackrock, Inc.

Q2 2026

SELL100.98 K714.95 K+-871.88 K-84.3%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUYNEW82.15 K581.62 K+82.15 K+0.0%0.00%
AC

Adar1 Capital Management, LLC

Q2 2026

BUYNEW39.52 K279.78 K+39.52 K+0.0%0.01%
AC

Aqr Capital Management LLC

Q2 2026

BUYNEW24.88 K176.13 K+24.88 K+0.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

BUYNEW18.86 K133.51 K+18.86 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL294.002.00 K+-8.17 K-94.6%0.00%